



Multiple Myeloma: From Pathogenesis to Diagnosis

A Clinical &
Pathophysiological Review



The Case Presentation


A 60-year-old gentleman presents with new exertional fatigue. He has no significant past medical history.

	Lab Results
	Hemoglobin: 10.6 g/dL (Low - Anemia) 
	Creatinine: 1.8 mg/dL (High - Renal Insufficiency) 
	Calcium: 11.2 mg/dL (High - Hypercalcemia) 
	Total Protein: 11 g/dL (High) vs. Albumin 3.1 g/dL (Low) 

Clinical Blue


Investigative Clue

Serum protein electrophoresis demonstrates a monoclonal IgA protein of 60 g/dL.




The Cell of Origin: The Plasma Cell

Plasma cells are the terminal differentiation of B-cells, primarily responsible for humoral immunity. They normally reside in the bone marrow (3–5%) and secrete polyclonal antibodies (IgG, IgM, IgA, IgD, IgE).




Pathogenesis: The Clonal Proliferation

Normal Response (Polyclonal)




Different plasma cells secrete a variety of immunoglobulins to fight infection.

Malignancy (Monoclonal)




A single malignant clone replicates uncontrollably. The clone secretes a single, identical immunoglobulin known as the Paraprotein or M-Protein.

Detecting the Clone: Serum Protein Electrophoresis (SPEP)



Proteins are separated by charge. In Myeloma, the monoclonal protein accumulates in the gamma region, creating a tall, narrow spike.

Decoding the M-Spike




The spike represents the physical quantity of the monoclonal protein. It is identified by its Heavy Chain and Light Chain.

- Common: IgG or IgA
- Rare: IgD or IgE
- Very Rare: IgM (Suggests Waldenström's)

Case Insight


Our patient has an IgA spike of 60 g/L—indicating a massive tumor burden.

The Spectrum: From MGUS to Symptomatic Myeloma



Clinical Manifestations: The CRAB Criteria

Symptomatic Myeloma is defined by end-organ damage.



These four pillars explain the constellation of symptoms in our patient case.

Bone Destruction & Hypercalcemia

Myeloma cells disrupt bone remodeling by increasing **Osteoclast** activity (bone eating) and decreasing **Osteoblast** activity (bone building). 🦠↑ 🦠↓.



Consequences:

- 🦴 Diffuse osteopenia
- 🦴 Lytic Lesions ("Punched-out" appearance)
- 🦴 Pathological fractures
- 🦴 Hypercalcemia (leached from destroyed bone)

Figure X. Lateral skull X-ray demonstrating multiple "punched-out" lytic lesions characteristic of myeloma.

Renal Insufficiency: The Mechanism of Injury

Primary Cause: Cast Nephropathy

Light chains bind with proteins in the tubules to form insoluble casts, obstructing flow.

Contributing Factors:




- Hypercalcemia



- Hyperviscosity




- NSAID use



Anemia & Immunodeficiency

Normocytic Anemia:
Caused by marrow infiltration (cancer cells crowding out RBC precursors) and renal failure (low EPO).

Infection: Patients are immunodeficient because the clonal antibodies are ineffective, and normal immunoglobulins are suppressed.



High protein levels reduce charge repulsion, causing RBCs to stack.

Neurological Complications


Spinal Cord Compression

Caused by paraspinal masses or vertebral body collapse. A medical emergency.



Peripheral Neuropathy

Direct damage to nerves by monoclonal proteins, or a side effect of chemotherapy.




Differential Diagnosis: Waldenström's Macroglobulinemia

Multiple Myeloma

- IgG or IgA
- Lytic Bone Lesions present

Waldenström's

- IgM (Pentameric - Large Molecule)
- Hyperviscosity Syndrome
- Organomegaly (Spleen/Liver)
- NO Lytic Bone Lesions



Retinal Vein
Engorgement ('Sausage
Link' effect due to
hyperviscosity).

Confirming the Diagnosis: The Triad


Diagnostic Criteria (Must have all three):

- ✓ **Monoclonal Protein:** M-Spike > 3 g/dL (or Bence Jones protein in urine)
- ✓ **Bone Marrow Clones:** Biopsy showing >10% CD138+ Plasma Cells
- ✓ **End Organ Damage:** Presence of CRAB features

The Patient's Verdict

- ✓ M-Spike 60g/L [Check]
- ✓ Anemia + Renal + Hypercalcemia [Check]

Diagnosis: Symptomatic Multiple Myeloma requiring treatment.



Summary & Epidemiology

- **Demographics:** Median age at diagnosis 65–70 years. Slight male predominance.
- **Incidence:** Represents 1% of all malignancies and 10% of hematologic malignancies.
- **Etiology:** Generally unknown; links to radiation, benzene, and chronic antigen stimulation.
- **Key Takeaway:** Recognize the progression from asymptomatic MGUS to the toxic, end-organ effects of Symptomatic Myeloma (CRAB).

